N@N

Bio-Rad Launches a Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG Kit for Its BioPlex 2200 System

_{//stocks-investing.news-articles.net/content/201 .. r-virus-igg-kit-for-its-bioplex-2200-system.html}
^{Published in Stocks and Investing on Monday, May 24th 2010 at 5:12 GMT by Market Wire}  

HERCULES, CA--(Marketwire - May 24, 2010) - Bio-Rad Laboratories, Inc. (NYSE: [ BIO ]) and (NYSE: [ BIO.B ]), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of the BioPlex^® 2200 MMRV IgG kit for use on the company's BioPlex^® 2200 system. The MMRV IgG kit (measles; mumps; rubella; and the varicella-zoster virus, which is commonly known as chicken pox) provides simultaneous results for the four tests that are commonly ordered together to determine a patient's susceptibility to MMRV.

The BioPlex 2200 MMRV IgG kit offers the advantage of multiplexing to deliver test results from a single patient sample. As a result, labs are able to generate test results quickly and with less effort. MMRV are infectious diseases that are preventable through vaccination. Maintaining high vaccination coverage and providing MMRV IgG results when an individual's status is uncertain is the most effective way to prevent disease outbreaks. Employees in healthcare facilities and military personnel, among others, are typically screened for MMRV IgG to ensure their safety.

"With the introduction of the BioPlex 2200 MMRV IgG kit, Bio-Rad offers a compelling menu for infectious disease serology and autoimmune testing laboratories," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "The MMRV IgG kit is the latest in our expanding menu of assays that run on our BioPlex 2200 system."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, consolidates workstations, and simplifies workflow.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: [ BIO ]) and (NYSE: [ BIO.B ]) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit [ www.bio-rad.com ].

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.